公开(公告)号：US20200254037A1

公开(公告)日：2020-08-13

申请号：US16637600

申请日：2018-08-06

Applicant: AMGEN INC. ,  GENENTECH, INC.

Inventor： Jennifer Lorraine Gansert ,  Sumita Shankar Bhatta ,  Joseph Paul Woodard, JR. ,  Edward Namserk Cha

IPC: A61K35/768 ,  A61K39/395 ,  A61K9/00 ,  A61P35/00

Abstract: Provided herein are methods of treating a subject with triple negative breast cancer or colorectal cancer. In exemplary embodiments, the method comprises administering to the subject a combination of an oncolytic virus, such as talimogene laherparepvec, and an anti-PD-L1 antibody, such as atezolizumab. In exemplary aspects, the oncolytic virus is administered to the subject at an initial dose followed by a second dose, wherein the initial dose is lower than the second dose. In exemplary aspects, the oncolytic virus is intrahepatically administered to the subject.

公开(公告)号：US20210332143A1

公开(公告)日：2021-10-28

申请号：US17249530

申请日：2021-03-04

Applicant: Genentech, Inc.

Inventor： Mahrukh Huseni ,  Joanna E. Klementowicz ,  Yijin Li ,  Li-Fen Liu ,  Sanjeev Mariathasan ,  Mark Merchant ,  Luciana Molinero ,  Lifen Wang ,  Nathaniel West ,  Patrick Williams ,  Chi Yung Yuen ,  Edward Namserk Cha ,  Yulei Wang

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/337 ,  A61K47/64

Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.